In Deal With Medicines Patent Pool, Bristol-Myers Squibb Agrees To Allow Generic Versions Of HCV Treatment To Be Sold In LMICs

Reuters: Bristol-Myers signs deal with U.N. group for generic hep C drug
“A United Nations-backed organization working to cut the price of HIV drugs said it had signed a deal with Bristol-Myers Squibb Co. to allow generic versions of the company’s hepatitis C drug to be sold in 112 low- and middle-income countries. … The Medicines Patent Pool said on Monday that Daklinza would now be available to nearly two-thirds of people affected by the disease in low- and middle-income countries…” (Nathan, 11/23).